In a 33-year-old female with widespread pruritic rashes unresponsive to prior oral terbinafine and itraconazole and recent terbinafine 250 mg twice daily plus topical ketoconazole, what is the most likely diagnosis and appropriate treatment?

This is NOT tinea incognito—stop all antifungals immediately and obtain proper diagnostic confirmation with KOH preparation, fungal culture, and skin biopsy before any further treatment.

Critical Diagnostic Re-evaluation Required

The failure to respond to multiple appropriate antifungal agents strongly suggests this is not a fungal infection. True dermatophyte infections, even resistant strains, typically show at least partial response to terbinafine or itraconazole 1. The complete lack of improvement after multiple systemic antifungals indicates you are likely treating the wrong diagnosis.

Immediate Actions Needed:

1. Stop all antifungal therapy immediately 2

• Continued terbinafine use without benefit exposes the patient to unnecessary hepatotoxicity risk
• The FDA label warns that liver function tests should be performed before prescribing terbinafine, and treatment should be discontinued if there's no clinical benefit 2

2. Obtain proper diagnostic confirmation NOW:

• KOH preparation from multiple active lesion sites
• Fungal culture with species identification and antifungal susceptibility testing
• Skin biopsy for histopathology to evaluate for:
  • Alternative diagnoses (psoriasis, eczema, drug reaction, lupus)
  • Deep fungal infection (Majocchi's granuloma) 3
  • Non-fungal inflammatory conditions

Alternative Diagnoses to Consider

Given the clinical presentation of widespread pruritic rashes unresponsive to antifungals:

Most Likely Alternatives:

Steroid-modified dermatosis (actual tinea incognito):

• If she used topical steroids before seeing you, this could mask typical fungal features
• However, systemic antifungals should still work—the lack of response argues against this

Drug reaction or contact dermatitis:

• Consider reaction to the antifungals themselves
• Topical ketoconazole can cause contact dermatitis

Psoriasis or eczema:

• Can present with widespread pruritic plaques
• May have been misdiagnosed as fungal infection initially

Scabies:

• Widespread pruritic rash
• Would not respond to antifungals
• Requires skin scraping for mites

If Fungal Infection is Confirmed

Only proceed with this pathway if diagnostic testing confirms dermatophytosis:

Consider Resistant or Atypical Organisms:

Emerging resistant strains:

• Trichophyton mentagrophytes genotype VII/VIII (T. indotineae) shows terbinafine resistance 4, 5
• These strains are increasingly reported globally and may require alternative therapy
• Antifungal susceptibility testing is mandatory before further treatment 4, 5

Non-dermatophyte moulds:

• Require different treatment approach
• Itraconazole has broader coverage than terbinafine for Candida and moulds 1

Treatment Algorithm for Confirmed Resistant Dermatophytosis:

If terbinafine-resistant organism confirmed:

• Switch to itraconazole 200 mg daily for 12 weeks 1, 4
• Alternative: Fluconazole 450 mg weekly for 6-12 months (less effective but option if itraconazole contraindicated) 1

If standard therapy continues to fail:

• Combination therapy: Terbinafine 250 mg + Itraconazole 200 mg daily 6
  • One study showed 90% cure rate with combination vs 35% with terbinafine alone and 50% with itraconazole alone
  • Duration: 3-6 weeks, extend if partial response
  • Monitor liver function closely with combination therapy 2

For deep dermatophyte infection (Majocchi's granuloma):

• Requires systemic therapy for 4-6 months 7, 3
• Itraconazole preferred over terbinafine for deep infections

Critical Safety Monitoring

Before any further antifungal therapy:

• Measure ALT and AST (mandatory per FDA label) 2
• Complete blood count (check for neutropenia) 2
• Assess for hepatotoxicity symptoms: nausea, fatigue, jaundice, dark urine 2

Common pitfall: Continuing ineffective antifungal therapy without confirming the diagnosis exposes patients to drug toxicity without benefit. The terbinafine dose you prescribed (250 mg BD) is actually double the standard licensed dose of 250 mg once daily 1, further increasing toxicity risk.

Bottom Line

You cannot diagnose tinea incognito clinically in a patient who has failed multiple antifungals—you need mycological proof. Stop treating empirically, obtain proper diagnostics (KOH, culture, biopsy), and only resume antifungal therapy if fungal infection is definitively confirmed with susceptibility testing to guide appropriate agent selection.